



► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjmed-2024-000920>).

For numbered affiliations see end of article.

Correspondence to: Dr Jennifer Miller, General Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA; jennifer.e.miller@yale.edu

Cite this as: *BMJMED* 2024;3: [doi:10.1136/bmjmed-2024-000920](https://doi.org/10.1136/bmjmed-2024-000920)

Received: 15 March 2024
Accepted: 21 May 2024



► <https://doi.org/10.1136/bmjmed-2024-000984>

Harnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies

Jennifer Miller ,¹ William Pelletiers,¹ Sakinah Suttiratana,^{1,2} Michael Ofosu Mensah ,³ Jason Schwartz,⁴ Reshma Ramachandran ,¹ Cary Gross,¹ Joseph S Ross ¹

ABSTRACT

OBJECTIVE To develop a reference standard based on US Food and Drug Administration and stakeholder guidance for pharmaceutical companies' policies on diversity in clinical trials and to assess these policies.

DESIGN Development of a reference standard and structured audit for clinical trial diversity policies.

SETTING 50 pharmaceutical companies selected from the top 500 by their market capitalizations in 2021 (the 25 largest companies and 25 non-large companies, randomly selected from the remaining 475 companies).

POPULATION Data from pharmaceutical company websites and annual reports. Policy guidance from the Pharmaceutical Research and Manufacturers of America, International Federation of Pharmaceutical Manufacturers and Associations, Biotechnology Industry Organization, International Committee of Medical Journal Editors, the US Food and Drug Administration, European Medicines Agency, and World Health Organization, up to 15 May 2023.

MAIN OUTCOME MEASURES Multicomponent measure based on distinct themes derived from FDA and stakeholder guidance.

RESULTS Reviewing FDA and stakeholder guidance identified 14 distinct themes recommended for improving diversity in clinical trials, which were built into a reference standard: (1) enrollment targets that reflect the prevalence of targeted conditions in populations, (2) broad eligibility criteria for trials, (3) diversity in the workforce, (4) identification and remedy of barriers to trial recruitment and retention, (5) incorporation of patient input into trial design, (6) health literacy, (7) multidimensional approaches to diversity, (8) sites with diverse providers and patient populations, (9) data collection after product approval, (10) diverse enrollment in every country where trials are conducted, (11) diverse enrollment should be a focus for all phases of clinical trials, not just later stage or pivotal trials, (12) varied trial design, (13) expanded access, and (14) public reporting of the personal characteristics of participants in trials. Applying this reference standard, 48% (24/50) of companies had no public policy on diversity in clinical trials; among those with policies, content varied widely. Large companies were more likely to have a public policy than non-large companies (21/25, 84% v 5/25, 20%, $P<0.001$). Large companies most frequently committed to using epidemiological based trial enrollment targets representing the prevalence of indicated conditions in various populations ($n=15$, 71%), dealing with barriers to trial recruitment ($n=15$, 71%), and improving patient awareness of trial opportunities ($n=14$, 67%). The location of the company was not associated with having a public diversity policy ($P=0.17$). The average company policy had five of the 14 commitments (36%, range 0-8) recommended in FDA and stakeholder guidance.

CONCLUSIONS The findings of the study showed that many pharmaceutical companies did not have

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ The US Food and Drug Administration (FDA) often approves new medicines based on studies in patients who are younger and more likely to identify as men and white than in patients with the clinical indications for treatment, which can negatively affect patient care, exacerbate inequalities in access to the benefits of clinical research, and undermine trust in new medical products and the research ecosystem
- ⇒ US policy efforts to improve diversity in clinical trials have spanned decades, with limited effect, raising the question of what more can be done to increase diversity and fair inclusion in trials
- ⇒ Previous literature suggests that corporate policies can be effective in achieving policy objectives, but the nature and content of corporate policies on diversity in clinical trials are poorly studied, as is what constitutes good corporate policy

WHAT THIS STUDY ADDS

- ⇒ A new reference standard was developed, based on FDA and stakeholder guidance, for assessing policies on diversity in clinical trials of pharmaceutical companies
- ⇒ The reference standard contains 14 distinct themes for improving diverse trial enrollment, recommended by the FDA and stakeholders, which includes use of enrollment targets that reflect the prevalence of targeted conditions in populations, broad eligibility criteria, and sites with diverse providers and patient populations
- ⇒ Applying the reference standard showed that many companies did not have public policies on diversity in clinical trials, and those with public policies varied widely and lacked important commitments, suggesting that companies should adopt more robust public policies to enhance diversity

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY

- ⇒ The findings of the study can inform pharmaceutical companies and other research sponsors on ways to improve their public policies on diversity in clinical trials and hence improve diverse and representative enrollment in clinical trials
- ⇒ These findings can also inform FDA and other stakeholders on the uptake of their published guidance for industry

public policies on diversity in clinical trials, although policies were more common in large than non-large companies. Policies that were publicly available varied widely and lacked important commitments recommended by stakeholder guidance. The results of the study suggest that corporate policies can be better leveraged to promote representation and fair inclusion in research, and implementation of FDA and stakeholder guidance.

Introduction

Regulatory approval of new drugs, biologics, and medical devices is often based on clinical studies with under-representation of older adults, women, and racial and ethnic minoritized individuals compared with patients treated for the indicated conditions in US clinical settings.¹⁻³ Research that is not representative of the patient's age, sex, race, and ethnic group is a public health and social justice concern because it can negatively affect patient care and exacerbate inequalities in access to the benefits of clinical research.⁴⁻⁵ Non-representative research can also undermine trust in new medical products and the legitimacy of the research ecosystem.⁶

Richard Pazdur, director of the the US Food and Drug Administration's Oncology Center of Excellence, recently commented that the US “has experienced tremendous social change,” and the FDA has “clearly heard from all patient groups that they want faces like theirs” participating in research to promote confidence in new medicines and vaccines.⁷ Policy efforts to improve representation in research span decades. Early efforts included introducing new requirements for the addition of a geriatric use section to drug labels in 1997,⁸ with information on drug safety and effectiveness for use in older adults, which was codified into law in 2007.⁹ In 1998, the FDA published a demographic rule,¹⁰ requiring new drug applications to present effectiveness and safety data by sex, age, and racial subgroups. More recently, the Food and Drug Omnibus Reform Act for 2023 newly requires research sponsors to develop and submit diversity action plans to the FDA for pivotal trials for therapeutics and medical devices. The diversity action plan should prespecify enrollment goals by age, sex, race, and ethnic group, and plans for how a sponsor intends to meet the enrollment goals.

Although more recent studies suggest that women might now be adequately represented in research for some conditions, older adults and racially and ethnically minoritized individuals, among other groups, are under-represented, raising the question of what more can be done to improve diversity and fair inclusion in enrollment in trials.¹¹ Previous literature suggests that corporate policies can be effective in driving organizational behavior toward policy objectives.¹²⁻¹⁴ But studies on the nature and content of corporate policies

on diversity in clinical trials are scarce, as well as what constitutes good corporate policy.

To help fill these knowledge gaps, we reviewed FDA and stakeholder guidance to develop a reference standard for policies on diversity in clinical trials of pharmaceutical companies. We then used this standard to assess the similarities between company policies and FDA and stakeholder guidance. We analyzed industry policies because industry sponsors most clinical trials supporting FDA product approvals.¹⁵ These findings can inform the FDA and other stakeholders on the uptake of their published guidance for industry. Our results can also inform companies on ways to improve their public policy commitments to increase representation and equitable access in clinical research.

Methods

We conducted a content analysis of relevant FDA and stakeholder guidance to develop a reference standard for a good policy on diversity in clinical trials for corporate pharmaceutical companies. We then used this standard to assess the policies of 50 pharmaceutical companies in terms of agreement with guidance from the FDA and other stakeholders. This study was conducted in accordance with the STROBE (strengthening the reporting of observational studies in epidemiology) reporting guideline.

Defining a reference standard for commitments to diversity in clinical trials

We established a reference standard for policies on diversity in clinical trials by conducting a content analysis of policy guidance from the Pharmaceutical Research and Manufacturers of America (PhRMA), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Biotechnology Industry Organization, International Committee of Medical Journal Editors, FDA, European Medicines Agency, and the World Health Organization, up to 15 May 2023.¹⁶⁻²² Guidance documents were reviewed for recurring themes on recommendations for sponsors' policies, procedures, and practices. A data structure was then developed to reflect a best practices standard of distinct thematic commitments to diversity in clinical trials.

We used a dual review process. Two researchers (JM and WP) independently analyzed each guidance document by conducting several readings of the texts to become familiar with their scope and identify key themes. In agreement with standard content analysis methods,²³ we extracted phrases or sentences with separate meaning units into an Excel file, and then condensed and categorized them into distinct themes describing recommended commitments to diversity in clinical trials (online supplemental appendix box 1). A codebook was created with all of the identified themes. Guidance documents were then reanalyzed applying the codebook to extract

language from the documents responsive to each theme. Researchers met to agree on the final identification and categorization of themes for the reference standard. Unanimous agreement was reached.

Company policy review

Next, the same two researchers independently used the codebook to analyze 50 corporate clinical trial policies, extracting sentences or fragments from policies into Excel that were relevant to each theme in the codebook. Researchers met to agree, through consensus, on the presence or absence of specific themes in each policy.

The 50 pharmaceutical companies were selected from the top 500 pharmaceutical companies by market capitalization in 2021 from <https://companiesmarketcap.com>. From this sample, we included the 25 largest companies by market capitalizations. We also included an exploratory sample of 25 randomly selected companies from the remaining 475 companies, referred to here as non-large companies, using Google's random number generator.

For each company, we manually searched their website and annual reports, with the search function, for the presence of a publicly available policy on diversity in clinical trials with the key terms “diversity” or “inclusion” or “representation” or “equity” AND “clinical trial” or “clinical research,” or “research.” We also conducted a Google search with the same key words to identify company policies. Copies of all identified policy pages were archived as PDFs on 6 July 2023. Membership of PhRMA by sponsors was determined on 1 March 2023.

Data analysis

We used descriptive statistics to summarize the proportion of guidance documents and corporate policies with distinct thematic commitments to diversity in clinical trials established in our reference standard. We used a Fisher exact test to assess whether company size, categorized as large versus non-large, was associated with a company having a public diversity policy. We used a χ^2 test to assess whether the location of the headquarters of the company was associated with having a public policy on diversity in clinical trials. Analyses were conducted in Microsoft Excel, version 15.11 (Redmond, WA).

Patient and public involvement

Patients and the public were not directly engaged in the conduct of this research study. Our thematic focus of diversity and fair inclusion in clinical research, however, has been identified by patients and the public as essential for developing a just and equitable research ecosystem.²⁴ We aim to engage patients, patient groups, and the public in the next phase of this project, using modified Delphi methods to gather perceptions on which of the leading indicators identified in this study are most likely to help improve diversity and representation in clinical trial enrollment.

Results

Defining a reference standard for commitments to diversity in clinical trials

We identified 14 themes in FDA and stakeholder guidance for improving diversity in clinical trials, which we built into a reference standard. The most common themes, appearing in five guidance documents, were recommendations for sponsors to: use targets for trial enrollment that reflected the incidence, prevalence, or severity of the condition or disease in various populations targeted by the trial; use broad eligibility criteria in trial protocols when scientifically appropriate; and identify and remedy barriers to trial recruitment and retention to diversify participation in trials. Facilitators for recruiting and retaining diverse patient populations recommended in the guidance included providing language access for participants with limited English proficiency, consideration of paying participants, reducing the frequency of required study visits, adoption of electronic communications and digital health technology tools to replace site visits, use of decentralized trials, and partnerships with community organizations in trial recruitment (online supplemental appendix box 2).

Four guidance documents recommended that sponsors should commit to increasing diversity in the workforce to improve participation in clinical trials. Four documents also recommended incorporating patient input and experiences into the design of the trial and product development, and conducting community and patient outreach and engagement to increase awareness of trial opportunities and health literacy. Also, four documents suggested that sponsors should adopt a multidimensional approach to diversity beyond sex, age, race, and ethnic group, to include other variables, particularly ancestry, gender, disability, pregnancy and lactation status, comorbidities, geography, socioeconomic status, and access to healthcare.

Two guidance documents recommended that sponsors should identify and use site locations for the trials with diverse providers who treat underserved or under-represented populations, collect data after product approval to enhance drug safety and efficacy data for diverse populations, when needed, and adopt a global perspective to diverse enrollment. Sponsors were recommended to implement policies and practices within their own organizations to support diverse enrollment into studies in every country where they conduct clinical trials or where the targeted disease burden is high. Two documents also recommended that diversity efforts should include transparent reporting of the personal characteristics of participants in the trial in publications and use new trial designs to facilitate broader population enrollment.

Of the reviewed guidance documents, the FDA guidance published in 2020 had the most commitments (10/14, 71%), which uniquely recommended

that sponsors should offer expanded access programs for patients who cannot participate in trials because of trial eligibility criteria and other reasons. IFPMA's guidance published in 2022 had nine of the 14 commitments (64%) and uniquely recommended that diversity efforts should be a focus for all phases of clinical trials, not just for later stage trials or pivotal trials. PhRMA's guidance published in 2020 had eight of the 14 commitments (57%) and uniquely suggested that sponsors should make their policies on diversity in clinical trials, or information about such practices, publicly available on their corporate websites. WHO guidance also had eight of the 14 commitments (57%). Guidance from the International Committee of Medical Journal Editors, updated in 2023, had three commitments (3/14, 21%). Guidance from the European Medicines Agency did not directly deal with any of the 14 commitments. We could not find public guidance on diversity in clinical trials from Biotechnology Industry Organization (figure 1).

Characteristics of sample sponsors

Of the 50 companies (25 large and 25 non-large) in our sample, we found that 56% (28/50) had their company headquarters in North America, 24% (12/50) in Europe and Central Asia, 14% (7/50) in East Asia Pacific, 4% (2/50) in South Asia, and 2% (1/50) in the Middle East and North Africa. No company had their headquarters in the Latin America or Caribbean region or in sub-Saharan Africa (online supplemental appendix table 1). Twenty (40%) of these 50 companies were members of PhRMA, comprising 67% of PhRMA's total membership (20/30). The median market capitalization in 2021 for large companies was about \$111.3 (£87.8; €103.9) billion (interquartile range \$60.3-240.6 billion) compared with \$1.4 billion (\$244 million to \$8.5 billion) for non-large companies in our sample.

Policies on diversity in clinical trials

Overall, 52% (26/50) of companies had a publicly available policy on diversity in clinical trials. The average policy had five of the 14 thematic commitments (36%, range 0-8%) recommended in FDA and stakeholder guidance. Publicly available policies were more common for large companies (21/25, 84%) than non-large companies (5/25, 20%; $P < 0.001$). The location of the company's headquarters, by region, was not associated with having a clinical trial diversity policy (North America: 13 of 28 (46%) companies had a policy; Europe and Central Asia: nine of 12 (75%) had a policy; and East Asia Pacific, Middle East, and North Africa, and South Asia: four of 10 (40%) had a policy; $P = 0.17$).

Large companies

Most large companies (21/25, 84%) had a publicly available policy stating a commitment to diversity in clinical trials. Although no large company's policy had all 14 themes in the FDA and stakeholder guidance, 13 of the 14 themes were covered by at least one large company's policy. No large company publicly committed to using varying trial designs and methodological approaches to facilitate broader population enrollment.

More than half of the large companies with a publicly available policy committed to: using targets for enrollment in trials that represented the incidence, prevalence, or severity of the condition or disease in various populations targeted by a trial (15/21, 71%); remedying barriers to trial recruitment and retention (15/21, 71%); conducting patient and community outreach to increase awareness of the opportunities of clinical trials and health literacy (14/21, 67%); and identifying and using trial sites with diverse populations and providers treating underserved or under-represented populations (12/21, 57%). Several large companies also committed to increasing diversity in the workforce (9/21, 43%) and transparently disseminating the personal characteristics of participants in the trial (9/21, 43%).

Fewer companies among those with publicly available policies committed to: incorporating patient input and experiences into the development of medical products (7/21, 33%); improving diverse enrollment for every country where a trial is conducted (5/21, 24%); offering expanded access to a product for individuals with life threatening conditions outside of a clinical trial (5/21, 24%); use of broad eligibility criteria in clinical trial protocols (4/21, 19%); using a multidimensional approach to diversity beyond sex, age, race, and ethnic group (4/21, 19%); collecting data after product approval to enhance drug safety and efficacy information for diverse populations (3/21, 14%); or adopting a focus on diversity efforts in all trials and not just for later stage trials or pivotal trials (3/21; 14%) (figure 2).

Non-large companies

A fifth of non-large companies (5/25) had a publicly available policy on diversity in clinical trials. The most common commitments were to use broad eligibility criteria in trial protocols (3/5, 60%) and to incorporate patient input and experiences into the development of medical products and the design of trials (3/5, 60%). At least two non-large companies also committed to using trial sites with diverse populations and providers treating underserved or under-represented populations, as well as to enhancing awareness of trial opportunities for the community and patients, and to health literacy. Only one non-large company committed to providing expanded access programs

Commitment (n=14)	Guidance							
	PhRMA	IFPMA	ICMJE	FDA 2022	FDA 2020	WHO	EMA	BIO
Use trial enrollment targets that represent the incidence, prevalence, or severity of the condition or disease in various populations targeted by a trial	X	X	X	X	X			
Use broad eligibility criteria in trial protocols as appropriate to improve trial participation	X	X		X	X	X		
Identify and remedy barriers to trial recruitment and retention	X	X		X	X	X		
Diversity in the workforce	X	X	X		X			
Incorporate patient input and experiences into medical product development and trial design	X	X			X	X		
Community and patient outreach and engagement to increase awareness of trial opportunities and health literacy	X	X			X	X		
Multidimensional approach to diversity		X		X	X	X		
Identify and use trial sites with diverse populations and providers that treat underserved or under-represented populations	X				X			
Collect data after product approval to enhance drug safety and efficacy data for diverse populations, when needed	X			X				
Adopt a global perspective to representative enrollment, with diverse enrollment in every country where trials are conducted or where a high disease burden exists		X				X		
Vary trial design and methodological approaches to facilitate broader population enrollment					X	X		
Publicly report personal characteristics of trial participants			X			X		
Diverse enrollment should be a focus for all clinical trial phases, not just in later stage trials or pivotal trials		X						
Offer expanded access					X			
Total number of commitments	8	9	3	5	10	8	0	No policy

Figure 1 | Commitments to diversity in clinical trials, recommended for adoption by research sponsors, in stakeholder guidance. X indicates that a guidance document recommended the commitment. PhRMA=Pharmaceutical Research and Manufacturers of America; IFPMA=International Federation of Pharmaceutical Manufacturers and Associations; BIO=Biotechnology Industry Organization; ICMJE=International Committee of Medical Journal Editors; FDA=US Food and Drug Administration; EMA=European Medicines Agency; WHO=World Health Organization

for those with life threatening conditions who do not qualify or cannot access a clinical trial.

Agreement between industry guidance and company commitments

Nearly all company members of PhRMA had a public policy on diversity in clinical trials (19/20,

95%). Examining whether PhRMA member policies matched their trade association's Industry-wide principles to enhance diversity in clinical trial participation, we found that no members committed to all PhRMA principles in their public policies. The most common commitments missing from policies included commitments to conduct additional studies




Figure 2 | Proportion of companies making public policy commitments to themes in US Food and Drug Administration and stakeholder guidance on diversity in clinical trials

after product approval, if needed, to enhance information on drug safety and efficacy for diverse populations, and the use of broad eligibility criteria for trials, when appropriate (figure 3).

Discussion

Principal findings

In this study, we developed a reference standard for evaluating the comprehensiveness of policies on diversity in clinical trials of pharmaceutical companies in incorporating key stakeholder guidance. We also characterized the public policies on diversity in clinical trials of 50 pharmaceutical companies, 25 large and an exploratory sample of 25 non-large companies, assessing their similarity to FDA and stakeholder guidance, based on the reference standard that we developed.

Overall, we found that only about half of the companies had a publicly available policy on diversity in clinical trials, with large companies more likely to have a public policy than our exploratory sample of non-large companies. Also, corporate policies varied

widely and often lacked important commitments recommended in guidance from FDA, PhRMA, WHO, and other stakeholders. For example, few companies with publicly available policies committed to incorporating patient input or experiences into product development or to using broad eligibility criteria for enrollment to increase representation, and even fewer publicly considered diversity in clinical trials beyond adequate representation by sex, age, race, and ethnic group.

Policy implications

These findings suggest that pharmaceutical corporate policies can be better leveraged to promote diversity in clinical research. Corporate policies are considered important elements of effective governance systems, by helping to identify and communicate long term corporate goals and align behaviors and corporate culture with defined goals.²⁵ Corporate policies enable shareholders to hold directors, and directors to hold management, accountable for implementation of policies.^{12 26 27} To achieve these benefits for diversity in clinical trials, our findings suggest two actions might be needed by pharmaceutical companies on the policy level. First, more companies should publicly communicate their commitments to diversity in clinical trials on their websites to increase public awareness and accountability. Second, companies should improve the comprehensiveness of their public policies.

Our reference standard established a series of 14 commitments recommended in stakeholder guidance that should be prioritized for inclusion in policies on diversity in clinical trials by pharmaceutical companies and other research funders. These commitments ranged from using targets for trial enrollment that reflect the incidence, prevalence, or severity of conditions or diseases in various populations targeted by a trial, to broad eligibility criteria for trials, and trial sites with diverse providers and patient populations. The reference standard




Figure 3 | Agreement between sponsor commitments and guidance from Pharmaceutical Research and Manufacturers of America (PhRMA) on diversity in clinical trials

also recommended a multidimensional approach to increasing diversity in trials by consideration of other factors, such as gender, disability, pregnancy and lactation status, comorbidities, geography, socioeconomic status, and access to healthcare. Beyond enrollment in trials, the reference standard looked at diversity in the workforce and patient engagement in the design of trials, among other commitments.

These 14 commitments generally align with and are responsive to barriers to participating in clinical trials and to facilitators identified in studies and surveys engaging patients and under-represented groups in research.^{28–30} Some barriers potentially not adequately considered in the analyzed stakeholder guidance and our developed reference standard, which have been identified in studies engaging patients, might include that: oncologists and patients are “more likely to consider clinical trials in advanced or refractory disease”; some patients might fear being allocated randomly to a placebo arm in research; patients have concerns about the side effects of experimental interventions; or “trial involvement would have a negative effect on the relationship with their physician.”³¹ The roles of religion, religious leaders, and patient access to health insurance also might not be fully considered in stakeholder guidance.³¹

Currently, few repercussions exist for research sponsors and pharmaceutical companies who fail to commit to recommendations in leading stakeholder guidance for improving diversity in clinical trials. In theory, trade associations, such as PhRMA and IFPMA, could remove member companies who violate their established principles and codes of conduct. PhRMA has precedence for this action. In 2017, PhRMA expelled 22 members who failed to meet their investment requirements for research and development because their business models were based on buying undervalued drugs and marking up their prices, rather than investing in researching and developing new products.³² Also, little to no monitoring exists of companies' commitments to diversity in clinical trials or incorporation of stakeholder guidance into corporate public policies. To strengthen monitoring as well as encourage adoption of select recommended commitments, we may build portions of this reference standard into the Good Pharma Scorecard, after engagement and validation with stakeholders. The Good Pharma Scorecard is an index that annually evaluates, rates, and ranks the performance of pharmaceutical companies on their bioethics and social responsibility. Currently, the Good Pharma Scorecard evaluates companies on whether they enroll representative patient populations in their pivotal trials supporting FDA approval of new oncology therapeutics.¹¹

Limitations of this study

Our study had some limitations. We focused on publicly available policies on diversity in clinical trials. Companies could have internal policy commitments not reflected in our findings. Also, our analyses focused on pharmaceutical companies and did not evaluate other major research sponsors, including companies who exclusively manufacture medical devices, or government agencies, such as the National Institutes of Health in the US. Our reference standard evaluated implementation of select stakeholder guidance; future work should validate its use across settings and assess buy-in from diverse stakeholders. Lastly, having a public commitment to diversity in clinical trial is important but does not guarantee successful implementation, and therefore an evaluation of outcome performance is critical, which we have previously done in other work.¹¹

A range of stakeholders must collaborate and be supported to deal with the lack of transparency and diversity in enrollment in clinical trials. The National Academies of Science, Engineering, and Medicine (NASEM) describes the role academic medical centers, community hospitals, institutional review boards, non-industry research funders, and medical journals should have in achieving a more equitable research ecosystem.³³ For example, NASEM's 2022 report states that, “the federal government has a notably prominent role and responsibility in achieving the goal of more inclusive research, as a primary funder of the research enterprise with taxpayer dollars, regulator of the processes of scientific research, gatekeeper to approvals for monetizing scientific discovery, and purchaser of new drugs and devices.” In this regard, the FDA is improving the reporting of the personal characteristics of participants in trials through the publication of its Drug Trials Snapshots, among other initiatives. NASEM suggests further governmental action, specifically that the Department of Health and Human Services form an interdepartmental taskforce to perform a variety of functions, including developing guidance on equitable compensation for research participation. NASEM also recommends that the National Institutes of Health should “standardize the submission of demographic characteristics for trials to ClinicalTrials.gov... so trial characteristics are labeled uniformly across the database and can be easily disaggregated, exported, and analyzed by the public.”

Currently, many variables are required to be reported and can be exported in a csv file from ClinicalTrials.gov entries, but the personal data of trial participants are generally not required for posting of trial registrations and results reporting or exportable when reported. Institutional review boards should evaluate planned enrollment goals in trial protocols for adequate diversity and representation, and consider requiring amendments before

approval of unjustified goals. NASEM suggests that the Centers for Medicare and Medicaid Services should “amend its guidance for coverage with evidence development to require that study protocols include... a plan for recruiting... representative participants” and a remediation process if coverage with evidence development studies fail to meet defined goals. Notwithstanding the role of these and other stakeholders in improving inclusive clinical research, pharmaceutical companies are key players because they sponsor most clinical trials supporting FDA product approvals.

Conclusions

In this study, we found that many pharmaceutical companies did not have public policies on diversity in clinical trials, and those that were publicly available varied widely and lacked important commitments. Large companies were more likely than non-large companies to have public policies on diversity in clinical trials. Our findings suggest that biopharmaceutical company policies can be better leveraged to improve diversity in clinical research and implementation of FDA and other stakeholder guidance.

AUTHOR AFFILIATIONS

¹General Internal Medicine, Yale School of Medicine, New Haven, CT, USA

²Yale Cancer Center, New Haven, CT, USA

³Yale School of Medicine, New Haven, CT, USA

⁴Yale University School of Public Health, New Haven, CT, USA

X Reshma Ramachandran @reshmagar and Joseph S Ross @jsross119

Contributors JM conceived of and designed the study. JM and WP extracted and analyzed the data. All authors had full access to the data and take responsibility for the integrity of the data and accuracy of the data analysis. JM led the drafting of the manuscript. All authors interpreted the data and critically revised the manuscript for important intellectual content, and approved the final manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. JM is the corresponding author and guarantor. Transparency: The lead author (the guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no support from any organization for the submitted work; JM serves as a board member of Bioethics International and as an advisor for Galatea Bio, and receives grant funding from the the US Food and Drug Administration (FDA) and Arnold Ventures outside the submitted work; RR reports receiving consultancy fees from ReAct Action on Antibiotic Resistance Strategic Policy Program, grants from the Stavros Niarchos Foundations for a project on public research and development, grants from the FDA outside the submitted work, and serving in volunteer unpaid positions on the board for the non-profit organization Universities Allied for Essential Medicines, North America and as chair of the Doctors for America FDA Task Force; CG reports receiving grants from Johnson & Johnson and the National Comprehensive Cancer Network (AstraZeneca), and personal fees from Genentech outside the submitted work; JS reports receiving grants from National Institutes of Health (NIH) during the conduct of the study; JSR reports receiving grants from the FDA, Johnson & Johnson, Medical Devices Innovation Consortium, Agency for Healthcare

Research and Quality, National Heart, Lung, and Blood Institute, and Arnold Ventures, and having been an expert witness at the request of relator’s attorney, the Greene Law Firm, in a qui tam lawsuit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen that was settled in September 2022; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethics approval The study did not require approval by an institutional review board approval because no human participants were involved.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Jennifer Miller <http://orcid.org/0000-0002-3591-369X>

Michael Oforu Mensah <http://orcid.org/0000-0002-3129-2718>

Reshma Ramachandran <http://orcid.org/0000-0003-3845-3606>

Joseph S Ross <http://orcid.org/0000-0002-9218-3320>

REFERENCES

- Loree JM, Anand S, Dasari A, *et al*. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. *JAMA Oncol* 2019;5:e191870. 10.1001/jamaoncol.2019.1870
- Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. *JAMA* 2004;291:2720–6. 10.1001/jama.291.22.2720
- Mendis S, Anand S, Karasinska JM, *et al*. Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies. *Oncologist* 2021;26:107–14. 10.1002/onco.13534
- Varma T, Jones CP, Oladele C, *et al*. Diversity in clinical research: public health and social justice imperatives. *J Med Ethics* 2023;49:200–3. 10.1136/medethics-2021-108068
- Rubin E. Striving for diversity in research studies. *N Engl J Med* 2021;385:1429–30. 10.1056/NEJMe2114651
- Schwartz AL, Alsan M, Morris AA, *et al*. Why diverse clinical trial participation matters. *N Engl J Med* 2023;388:1252–4. 10.1056/NEJMp2215609
- Kolata G. FDA panel rejects Lilly’s cancer drug tested only in China. *New York Times* 2022. Available: <https://www.nytimes.com/2022/02/10/health/fda-cancer-drug-china.html>
- 62 Fed. reg. 45313, 4325. 1997.
- US Food and Drug Administration. CFR - code of Federal regulations title 21 [10. 21 C.F.R. § 201.57(C)(9)(V). 2007. Available: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=201.57>
- Code of Federal Regulations. [21 C.F.R 314.50 and 21 C.F.R 312.33]. 2023. Available: <https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314#:~:text=Subpart%20B—Applications-,§%20314.50%20Content%20and%20format%20of%20a%20NDA.,copy%2C%20and%20a%20field%20copy>
- Varma T, Mello M, Ross JS, *et al*. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study. *BMJ Med* 2023;2:e000395. 10.1136/bmjmed-2022-000395

- 12 Hassink H, de Vries M, Bollen L. A content analysis of whistleblowing policies of leading European companies. *J Bus Ethics* 2007;75:25–44. 10.1007/s10551-006-9236-9
 - 13 Trevino LK. Ethical decision making in organizations: a person-situation Interactionist model. *Acad Manage Rev* 1986;11:601. 10.2307/258313
 - 14 Ferrell OC, Gresham LG. A contingency framework for understanding ethical decision making in marketing. *J Marketing* 1985;49:87–96. 10.1177/002224298504900308
 - 15 Zhou EW, Jackson MJ, Ledley FD. Spending on phased clinical development of approved drugs by the US National Institutes of Health compared with industry. *JAMA Health Forum* 2023;4:e231921. 10.1001/jamahealthforum.2023.1921
 - 16 PhRMA. Improving clinical trial diversity. PhRMA's equity initiative. 2020. Available: <https://phrma.org/Equity/clinical-trial-diversity#about-this-effort>
 - 17 IFPMA. Diversity and inclusion in clinical trials: bioethical perspective and principles. IFPMA publications. 2022. Available: <https://ifpma.org/publications/diversity-and-inclusion-in-clinical-trials-bioethical-perspective-and-principles/>
 - 18 Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials guidance for industry: draft guidance for industry. *FDA Guidance Documents* 2022. Available: <https://www.fda.gov/media/157635/download>
 - 19 Center for Drug Evaluation and Research. Enhancing the diversity of clinical trial populations — eligibility criteria, enrollment practices, and trial designs; draft guidance for industry. 2020. Available: <https://www.fda.gov/media/127712/download>
 - 20 ICMJE. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. 2023. Available: <https://www.icmje.org/icmje-recommendations.pdf> [Accessed 18 May 2023].
 - 21 Regulation (EU) no 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials in medicinal products for human use and repealing directive 2001/20/EC. *Off J* 2014;158:1. Available: <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32014R0536>
 - 22 WHO guidance for best practices for clinical trials. 2023. Available: https://cdn.who.int/media/docs/default-source/research-for-health/2023-07_who-guidance-for-best-practices-for-clinical-trials_draft-for-public-consultation.pdf?sfvrsn=7a5c9fa5_3 [Accessed 10 Mar 2024].
 - 23 Kleinheksel AJ, Rockich-Winston N, Tawfik H, *et al*. Demystifying content analysis. *Am J Pharm Educ* 2020;84:7113. 10.5688/ajpe7113
 - 24 Psychiatric News, American Psychiatric Association. APA's government, policy and advocacy update. 2022. Available: <https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2022.08.8.51>
 - 25 Dzeng E, Batten JN, Dohan D, *et al*. Hospital culture and intensity of end-of-life care at 3 academic medical centers. *JAMA Intern Med* 2023;183:339–48. 10.1001/jamainternmed.2023.2450
 - 26 Braithwaite J, Travaglia JF. An overview of clinical governance policies, practices and initiatives. *Aust Health Rev* 2008;32:10–22. 10.1071/aho80010
 - 27 Goldacre B, Lane S, Mahtani KR, *et al*. Pharmaceutical companies' policies on access to trial data, results, and methods: audit study *BMJ*. *BMJ* 2017;358:j3334. 10.1136/bmj.j3334
 - 28 Shea L, Pesa J, Geonnotti G, *et al*. Improving diversity in study participation: patient perspectives on barriers, racial differences and the role of communities. *Health Expect* 2022;25:1979–87. 10.1111/hex.13554
 - 29 Mills EJ, Seely D, Rachlis B, *et al*. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. *Lancet Oncol* 2006;7:141–8. 10.1016/S1470-2045(06)70576-9
 - 30 Capers Q IV, Johnson A, Berlachar K, *et al*. The urgent and ongoing need for diversity, inclusion, and equity in the cardiology workforce in the United States. *JAHA* 2021;10:e018893. 10.1161/JAHA.120.018893
 - 31 Meropol NJ, Buzaglo JS, Millard J, *et al*. Barriers to clinical trial participation as perceived by oncologists and patients. *J Natl Compr Canc Netw* 2007;5:655–64. 10.6004/jnccn.2007.0067
 - 32 Palmer E. PhRMA Expels 22 members with new R&D rules as it works to burnish its image. 2017. Available: <https://www.fiercepharma.com/pharma/phrma-expels-22-members-new-r-d-rules-as-its-works-to-burnish-its-image>
 - 33 National Academies of Sciences, Engineering, and Medicine. Improving representation in clinical trials and research: building research equity for women and underrepresented groups. Washington, DC: The National Academies Press, 2022.
- Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjmed-2024-000920>).